Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The primary goal of this study is to evaluate the effect of PF-04360365 on the clearance of
ABETA from the CSF (cerebrospinal fluid) in patients with mild Alzheimer's disease and
healthy volunteers. Additionally, the study will assess the pharmacokinetics of PF-04360365,
pharmacokinetic and pharmacodynamic relationships in plasma and CSF and the safety and
tolerability of single doses of PF-04360365 administered to patients with Alzheimer's disease
and healthy volunteers.